Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Intravenous Immunoglobulin Treatment is Associated with a Reduced Risk of Developing Alzheimer's Disease and Related Disorders
March 14th, 2008
The risk of developing Alzheimer's Disease and Related Disorders (ADRD) may be reduced by about 40 percent in patients previously treated with intravenous immunoglobulin (IVIG) according to a study presented today at the 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. The findings were presented by Howard Fillit, M.D., clinical professor of geriatrics, medicine and neurobiology at The Mount Sinai-NYU Medical Center in New York, and executive director of the Alzheimer's Drug Discovery Foundation. The study was based on Surveillance Data Inc.'s (SDI's) HIPAA-compliant, longitudinal medical claims database. IVIG -- an antibody...
Source: Health Business Week (2008-03-14)
|
